I learned from AstraZeneca that its injectable detrutuzumab has been approved as the fifth new indication in China. The single drug is used to treat adult breast cancer patients with unresectable or metastatic hormone receptor positive HER2 low expression or very low HER2 expression who have progressed through one or more endocrine treatments in the stage of metastatic disease. Destrastuzumab is a DXD antibody-conjugated drug targeting HER2. It was developed by Daiichi Sankyo and developed and commercialized in collaboration with AstraZeneca and Daiichi Sankyo. Previously, it was approved in China to treat tumors such as breast cancer, lung cancer, and breast cancer.

I learned from AstraZeneca that its injectable detrutuzumab has been approved as the fifth new indication in China. The single drug is used to treat adult breast cancer patients with unresectable or metastatic hormone receptor positive HER2 low expression or very low HER2 expression who have progressed through one or more endocrine treatments in the stage of metastatic disease. Destrastuzumab is a DXD antibody-conjugated drug targeting HER2. It was developed by Daiichi Sankyo and developed and commercialized in collaboration with AstraZeneca and Daiichi Sankyo. Previously, it was approved in China to treat tumors such as breast cancer, lung cancer, and breast cancer.